Clinical trial · Interventional
Assessment of Glypican 3 as Apredictive Marker in Colorectal Cancer Patients
Assessment of Glypican 3 as a Predictive Marker in Colorectal Cancer Patients
NCT04728139CI-TRIAL-00055962unknownN/AClinicalTrials.gov clinicaltrialsProvenance
- Source
- ClinicalTrials.gov
- Retrieved
- Sep 8, 2026
- Layer
- normalized (units and labels harmonized; values unchanged)
- Run
- ING-CLINICALTRIALS-20260908-000001
Summary
Brief summary (as posted)
* Evaluation Of Glypican 3 in serum of colorectal cancer patients . * Correlation between Glypican 3 and clinicopathological characteristics of colorectal cancer .
Conditions
Conditions (1)
Free-text conditions as registered, with the CancerIndex entity they were reconciled to and the match type.
| Condition (as posted) | Mapped entity | Match | Confidence |
|---|---|---|---|
| Colorectal Cancer | Malignant Colorectal Neoplasm | CURATED_BROADER | 0.80 |
Interventions
Interventions (1)
| Intervention | Type | Mapped drug | Match |
|---|---|---|---|
| glypican 3 | Diagnostic Test | — | UNRESOLVED |
Design
Arms and outcomes
Arms (2)
- type
- ACTIVE_COMPARATOR
- label
- patients with colorecta cancer
- interventionNames
- Diagnostic Test: glypican 3
- type
- NO_INTERVENTION
- label
- healthy individuals
Primary outcomes (1)
- measure
- Evaluation of Glypican 3 role as a predictive and diagnostic marker of colorectal marker .
- timeFrame
- 3 years
- description
- measurment of GLYPICAN 3 level in serum of colorectal patients using ELISA method
Secondary outcomes (1)
- measure
- Addition of Glypican 3 to the routine markers of colorectal cancer . - Correlatin of this marker with the disease pathology and management procedures .
Eligibility
Eligibility (as posted)
- Sex
- All
Show eligibility criteria text
Inclusion Criteria: * Patients with colorectal cancer and admitted to south egypt cancer institute . Exclusion Criteria: * Other malignant diseases . * Patients received chemotherapy for colorectal cancer .
References
Publications (13)
- BACKGROUNDTerzic J, Grivennikov S, Karin E, Karin M. Inflammation and colon cancer. Gastroenterology. 2010 Jun;138(6):2101-2114.e5. doi: 10.1053/j.gastro.2010.01.058. PMID 20420949
- BACKGROUNDIbrahim AS, Khaled HM, Mikhail NN, Baraka H, Kamel H. Cancer incidence in egypt: results of the national population-based cancer registry program. J Cancer Epidemiol. 2014;2014:437971. doi: 10.1155/2014/437971. Epub 2014 Sep 21. PMID 25328522
- BACKGROUNDIjaz B, Formentin E, Ronci B, Locato V, Barizza E, Hyder MZ, Lo Schiavo F, Yasmin T. Salt tolerance in indica rice cell cultures depends on a fine tuning of ROS signalling and homeostasis. PLoS One. 2019 Apr 30;14(4):e0213986. doi: 10.1371/journal.pone.0213986. eCollection 2019. PMID 31039145
- BACKGROUNDFilmus J, Selleck SB. Glypicans: proteoglycans with a surprise. J Clin Invest. 2001 Aug;108(4):497-501. doi: 10.1172/JCI13712. No abstract available. PMID 11518720
- BACKGROUNDShirakawa H, Kuronuma T, Nishimura Y, Hasebe T, Nakano M, Gotohda N, Takahashi S, Nakagohri T, Konishi M, Kobayashi N, Kinoshita T, Nakatsura T. Glypican-3 is a useful diagnostic marker for a component of hepatocellular carcinoma in human liver cancer. Int J Oncol. 2009 Mar;34(3):649-56. doi: 10.3892/ijo_00000190. PMID 19212669
- BACKGROUNDSarrazin S, Lamanna WC, Esko JD. Heparan sulfate proteoglycans. Cold Spring Harb Perspect Biol. 2011 Jul 1;3(7):a004952. doi: 10.1101/cshperspect.a004952. PMID 21690215
- BACKGROUNDFico A, Maina F, Dono R. Fine-tuning of cell signaling by glypicans. Cell Mol Life Sci. 2011 Mar;68(6):923-9. doi: 10.1007/s00018-007-7471-6. Epub 2011 Feb 22. PMID 18087675
- BACKGROUNDMatsuda K, Maruyama H, Guo F, Kleeff J, Itakura J, Matsumoto Y, Lander AD, Korc M. Glypican-1 is overexpressed in human breast cancer and modulates the mitogenic effects of multiple heparin-binding growth factors in breast cancer cells. Cancer Res. 2001 Jul 15;61(14):5562-9.